Skip to main content
. 2018 Jul 30;27(1):19–24. doi: 10.1136/ejhpharm-2017-001453

Table 1.

Incident cohort of patients with metastatic breast cancer

Percentage% Number of patients Source
Incident cases of mBC 100 2923 1 9–11
HER2−/HR+ 54 1575 3
HER2+/HR+ 18 520 3
HER2+/HR− 11 324 3
Triple negative 17 503 3

HER2, human epidermal growth factor receptor 2; HR, hormonal receptor; mBC, metastatic breast cancer.